Document is current
Any future updates will be listed below
-
Authors
San José Cáceres, Antonia
Wilkinson, Emma
Cooke, Jennifer
Baskett, Victoria
Blackmore, Charlotte
Crawley, Daisy Victoria
Durkin, Allison
Halpern, Danielle
Núñez, María
Siper, Page
Murphy, Declan G.
Foss-Feig, Jennifer
Kolevzon, Alexander
Loth, Eva
-
Funding
Funding for this research was provided by:
innovative medicines initiative (115300, 777394)
seventh framework programme (FP7/2007-2013)
beatrice and samuel a. seaver foundation (R34 MH100276)
ministerio de ciencia, innovación y universidades (BGP18700186)
comunidad de madrid (S12/PBG/2020-00016)
- License Information
-
More Information
Article History
Received: 30 July 2021
Accepted: 26 July 2024
First Online: 19 November 2024
Declarations
:
: In the UK, the project was approved by the National Research Ethics Service (NRES) Committee London – Queen Square, under reference 15/LO/0305. All volunteers and their families gave appropriate consent/assent to participate in the study. In the US, the project was approved by the Institutional Review Board at the Mount Sinai Hospital. All participants and their families gave appropriate consent to participate in the study.
: NA.
: AK receives research support from AMO Pharma and consults to Ovid Therapeutics, Acadia, and Alkermes. ASJC has been a consultant for F. Hoffmann-La Roche Ltd, consults for Servier and Signant Health, and she has been involved in clinical trials conducted by Servier. The present work is unrelated to the above grants and relationships. All other authors have no competing interests to declare (EL, JC, JFF, PS, EW, DH, AD, DVC, VB, CB, DGM, MN).
